BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 26848684)

  • 1. A Potential of an Anti-HTLV-I gp46 Neutralizing Monoclonal Antibody (LAT-27) for Passive Immunization against Both Horizontal and Mother-to-Child Vertical Infection with Human T Cell Leukemia Virus Type-I.
    Fujii H; Shimizu M; Miyagi T; Kunihiro M; Tanaka R; Takahashi Y; Tanaka Y
    Viruses; 2016 Feb; 8(2):. PubMed ID: 26848684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a neutralization epitope on the envelope gp46 antigen of human T cell leukemia virus type I and induction of neutralizing antibody by peptide immunization.
    Tanaka Y; Zeng L; Shiraki H; Shida H; Tozawa H
    J Immunol; 1991 Jul; 147(1):354-60. PubMed ID: 1711082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibodies to the envelope glycoprotein of human T cell leukemia virus type 1 robustly activate cell-mediated cytotoxic responses and directly neutralize viral infectivity at multiple steps of the entry process.
    Kuo CW; Mirsaliotis A; Brighty DW
    J Immunol; 2011 Jul; 187(1):361-71. PubMed ID: 21646298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple neutralizing B-cell epitopes of human T-cell leukemia virus type 1 (HTLV-1) identified by human monoclonal antibodies. A basis for the design of an HTLV-1 peptide vaccine.
    Baba E; Nakamura M; Tanaka Y; Kuroki M; Itoyama Y; Nakano S; Niho Y
    J Immunol; 1993 Jul; 151(2):1013-24. PubMed ID: 7687611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The neutralizing function of the anti-HTLV-1 antibody is essential in preventing in vivo transmission of HTLV-1 to human T cells in NOD-SCID/γcnull (NOG) mice.
    Saito M; Tanaka R; Fujii H; Kodama A; Takahashi Y; Matsuzaki T; Takashima H; Tanaka Y
    Retrovirology; 2014 Aug; 11():74. PubMed ID: 25163482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The humoral immune response to human T-cell lymphotropic virus type 1 envelope glycoprotein gp46 is directed primarily against conformational epitopes.
    Hadlock KG; Rowe J; Foung SK
    J Virol; 1999 Feb; 73(2):1205-12. PubMed ID: 9882322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequence variations in the amino- and carboxy-terminal parts of the surface envelope glycoprotein of HTLV type 1 induce specific neutralizing antibodies.
    Tallet B; Astier-Gin T; Moynet D; Londos-Gagliardi D; Guillemain B
    AIDS Res Hum Retroviruses; 2001 Mar; 17(4):337-48. PubMed ID: 11242520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A source of glycosylated human T-cell lymphotropic virus type 1 envelope protein: expression of gp46 by the vaccinia virus/T7 polymerase system.
    Arp J; LeVatte M; Rowe J; Perkins S; King E; Leystra-Lantz C; Foung SK; Dekaban GA
    J Virol; 1996 Nov; 70(11):7349-59. PubMed ID: 8892853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A peptide-based human T cell leukemia virus type I vaccine containing T and B cell epitopes that induces high titers of neutralizing antibodies.
    Baba E; Nakamura M; Ohkuma K; Kira J; Tanaka Y; Nakano S; Niho Y
    J Immunol; 1995 Jan; 154(1):399-412. PubMed ID: 7527817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralizing human monoclonal antibodies to conformational epitopes of human T-cell lymphotropic virus type 1 and 2 gp46.
    Hadlock KG; Rowe J; Perkins S; Bradshaw P; Song GY; Cheng C; Yang J; Gascon R; Halmos J; Rehman SM; McGrath MS; Foung SK
    J Virol; 1997 Aug; 71(8):5828-40. PubMed ID: 9223472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epitope mapping of human monoclonal antibodies recognizing conformational epitopes within HTLV type 1 gp46, employing HTLV type 1/2 envelope chimeras.
    Hadlock KG; Yang Q; Rowe J; Foung SK
    AIDS Res Hum Retroviruses; 2002 Jan; 18(1):57-70. PubMed ID: 11804557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequence analysis of an immunogenic and neutralizing domain of the human T-cell lymphoma/leukemia virus type I gp46 surface membrane protein among various primate T-cell lymphoma/leukemia virus isolates including those from a patient with both HTLV-I-associated myelopathy and adult T-cell leukemia.
    Sherman MP; Dube S; Spicer TP; Kane TD; Love JL; Saksena NK; Iannone R; Gibbs CJ; Yanagihara R; Dube DK
    Cancer Res; 1993 Dec; 53(24):6067-73. PubMed ID: 8261424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mother-to-child transmission of human T-cell lymphotropic virus type I (HTLV-I) in Jamaica: association with antibodies to envelope glycoprotein (gp46) epitopes.
    Wiktor SZ; Pate EJ; Murphy EL; Palker TJ; Champegnie E; Ramlal A; Cranston B; Hanchard B; Blattner WA
    J Acquir Immune Defic Syndr (1988); 1993 Oct; 6(10):1162-7. PubMed ID: 7692038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of monoclonal antibodies directed against the gp46 of human T-cell leukemia virus type I.
    Edouard E; Legrand E; Astier-Gin T; Dalibart R; Geoffre S; Dalbon P; Guillemain B; Londos-Gagliardi D
    Leukemia; 1994 Apr; 8 Suppl 1():S60-4. PubMed ID: 7512182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mapping of immunogenic regions of human T cell leukemia virus type I (HTLV-I) gp46 and gp21 envelope glycoproteins with env-encoded synthetic peptides and a monoclonal antibody to gp46.
    Palker TJ; Tanner ME; Scearce RM; Streilein RD; Clark ME; Haynes BF
    J Immunol; 1989 Feb; 142(3):971-8. PubMed ID: 2563272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation and characterization of monoclonal antibodies against multiple epitopes on the C-terminal half of envelope gp46 of human T-cell leukemia virus type-I (HTLV-I).
    Tanaka Y; Yasumoto M; Nyunoya H; Ogura T; Kikuchi M; Shimotohno K; Shiraki H; Kuroda N; Shida H; Tozawa H
    Int J Cancer; 1990 Oct; 46(4):675-81. PubMed ID: 1698731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of novel neutralization-inducing regions of the human T cell lymphotropic virus type I envelope glycoproteins with human HTLV-I-seropositive sera.
    Desgranges C; Souche S; Vernant JC; Smadja D; Vahlne A; Horal P
    AIDS Res Hum Retroviruses; 1994 Feb; 10(2):163-73. PubMed ID: 8198868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of new epitopes recognized by human monoclonal antibodies with neutralizing and antibody-dependent cellular cytotoxicity activities specific for human T cell leukemia virus type 1.
    Kuroki M; Nakamura M; Itoyama Y; Tanaka Y; Shiraki H; Baba E; Esaki T; Tatsumoto T; Nagafuchi S; Nakano S
    J Immunol; 1992 Aug; 149(3):940-8. PubMed ID: 1378869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of type-specific linear epitopes in the glycoproteins gp46 and gp21 of human T-cell leukemia viruses type I and type II using synthetic peptides.
    Horal P; Hall WW; Svennerholm B; Lycke J; Jeansson S; Rymo L; Kaplan MH; Vahlne A
    Proc Natl Acad Sci U S A; 1991 Jul; 88(13):5754-8. PubMed ID: 1712105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of neutralizing antibodies against human T-cell leukemia virus type 1 using a cell-free infection system and polymerase chain reaction.
    Haraguchi Y; Yang DW; Handa A; Shimizu N; Tanaka Y; Hoshino H
    Int J Cancer; 1994 Nov; 59(3):416-21. PubMed ID: 7927951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.